Vol. 3 No. 3 (2023)
Reimbursement Reviews

Eptinezumab (Vyepti)

decorative image

Published March 15, 2023

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses eptinezumab (Vyepti), 100 mg/mL solution for IV infusion.
  • Indication: Indicated for the prevention of migraine in adults who have had at least 4 migraine days per month.